Context: Low maternal free T4 (FT4) has been associated with poor child neurodevelopment in some single-center studies. Evidence remains scarce for the potential adverse effects of high FT4 and whether associations differ in countries with different iodine status.
Conclusions: Low maternal FT4 was consistently associated with a lower IQ across the cohorts. Further studies are needed to replicate the findings of autistic traits and investigate the potential modifying role of maternal iodine status. FT4 seems a reliable marker of fetal thyroid state in early pregnancy, regardless of the type of immunoassay. (J Clin Endocrinol Metab 103: [2967] [2968] [2969] [2970] [2971] [2972] [2973] [2974] [2975] [2976] [2977] [2978] [2979] 2018) T hyroid hormone regulates crucial processes of brain development, including the proliferation, migration, and differentiation of neuronal cells, as shown in animal studies (1, 2). Because the fetal thyroid gland is not functionally mature until approximately week 18 of pregnancy (3), the fetus is dependent on placental transfer of maternal thyroid hormone during this period. Adequate maternal thyroid hormone concentrations during early pregnancy are therefore essential for optimal fetal brain development.
Previous studies focused mainly on the possible adverse effects of low maternal hormone availability on fetal brain development. In several studies, either overt hypothyroidism or low maternal free T4 (FT4) was associated with a lower child IQ (4) (5) (6) (7) (8) , lower gray matter volume (4), a greater risk of autistic traits (8) , impaired psychomotor function (10) , and schizophrenia (11) . Although the association of high maternal FT4 on child neurodevelopment has been less well studied, experimental evidence from rodents has indicated that high hormone availability might also have adverse effects (12) (13) (14) (15) (16) (17) (18) . A recent study from The Netherlands has shown that high maternal FT4 is associated with lower IQ and gray matter volumes in the child (4) . However, it is unclear whether these findings from an iodine-sufficient population in The Netherlands (19) can be extrapolated to other countries with a different iodine status and whether high maternal FT4 is also associated with other adverse neurodevelopmental outcomes other than IQ.
Neither of the two randomized controlled trials that studied the effect of levothyroxine treatment in women with subclinical hypothyroidism or hypothyroxinemia on child IQ showed any benefit of treatment (20, 21) . However, these negative results could be ascribable to a relatively late start of treatment in both trials (13 weeks and 16 to 18 weeks, respectively), a relatively high dose was given that might have led to potential overtreatment (20) , or a lack of power to detect the expected 3-to 4-point difference in IQ (21, 22) . Therefore, further studies are required to better quantify and replicate the potential effects of both low and high maternal thyroid hormone availability on fetal neurodevelopment. These studies can help improve the design of future controlled trials.
The aim of the present study was to investigate the association of maternal thyroid function in early pregnancy across the full range of FT4 and TSH concentrations with the child's IQ and autistic traits in 3 prospective birth cohorts.
Materials and Methods

Study design and populations
For the present study, we used individual participant data from three prospective population-based birth cohorts: Infancia y Medio Ambiente [INMA (Environment and Childhood project), Spain, three regions] (23), Generation R (The Netherlands) (24) , and the Avon Longitudinal Study of Parents and Children (ALSPAC, United Kingdom) (25) . In INMA, the eligible study participants were pregnant women with a singleton pregnancy residing in the regions of Valencia, Sabadell, and Gipuzkoa from November 2003 to January 2008. In Generation R, the eligible study participants were pregnant women living in the Rotterdam area with an expected delivery date from April 2002 to January 2006. In ALSPAC, the eligible study participants resided in a defined area in the southwest of England, with an expected date of delivery from April 1991 to December 1992 [the study website of ALSPAC contains details of all the data available through a fully searchable data dictionary (26) ]. For the present study, eligible women were enrolled in the three cohorts during the first half of pregnancy (#18th week of gestation). Women with multiple pregnancies or fertility treatment and/or using medication affecting the thyroid or having a known thyroid disease were excluded (Fig. 1) . The local ethical committees approved the present study at study enrollment; all participants and/or parents or guardians of the children provided informed consent.
Thyroid function
Thyroid function was measured in serum samples stored at 280°C (INMA and Generation R) or 220°C (ALSPAC). The samples were obtained at early pregnancy [(mean 6 SD) gestational age: INMA, 13.1 6 1.3 weeks; Generation R, 13.4 6 2.0 weeks; ALSPAC, 11.0 6 3.2 weeks] (Table 1) . Different assays were used to measure FT4 and TSH (Supplemental Table 1 ). Although thyroid peroxidase antibody (TPOAb) was not measured in INMA, TPOAb measurements were available from Generation R and ALSPAC. The FT4 and TSH concentrations were logarithmically transformed, and cohort-specific SD scores were calculated with a mean of 0 and a SD of 1 based on the data of TPOAb-negative women, as advocated by the guidelines when defining population-based reference ranges (27) .
Hypothyroxinemia [normal (2.5th-97.5th percentile) TSH; low (,2.5th percentile) FT4], subclinical hypothyroidism [high (.97.5th percentile) TSH, normal FT4], and subclinical hyperthyroidism (low TSH, normal FT4) were defined according to the 2.5th and 97.5th population-based percentiles of the whole study population in INMA, because TPOAb measurements were not available. Thyroid disease entities were defined using the same population-based percentiles in Generation R and ALSPAC. However, in these cohorts, the population-based percentiles were based on the results from TPOAb-negative women. The reference group consisted of euthyroid women (TSH and FT4 between the 2.5th and 97.5th percentiles).
Additionally, to improve the statistical power, we identified the thyroid disease entities using the 5th and 95th population-based percentiles. The untransformed 2.5th and 97.5th populationbased percentiles based on TPOAb-negative women when possible were 0.14 and 3.86, 0.05 and 4. 
Nonverbal and verbal IQ
In INMA, nonverbal and verbal IQ were assessed by a psychologist at a median age of 4.6 years using the McCarthy Scales of Children's Abilities (28) . In Generation R, nonverbal IQ was assessed by trained staff at a median age of 6.0 years using a subset of the Snijders Oomen Nonverbal Intelligence Test (2.5-7-Revised) (29) , and verbal IQ was estimated by the parent-reported short form of the McArthur Communicative Development Inventory (30) obtained at a median age of 1.5 years. In ALSPAC, nonverbal and verbal IQ were assessed by trained staff at a median age of 8.6 years using the Wechsler Intelligence Scale For Children, third UK edition (31) . To homogenize the different scores, raw cohort-specific scores were standardized to a mean of 100 and a SD of 15 (new score = 100 + 15 3 SD).
Autistic traits within the clinical range
Autistic traits are symptoms that represent subclinical deficits in social behavior, communication, and or restricted, repetitive patterns of behavior common to autism spectrum disorder (ASD) but that do not meet the clinical ASD diagnosis (32) . Autistic traits within the clinical range were defined as the presence of an autistic traits score greater than the specific cutoff for each assessment tool, which had been previously validated in other studies to detect children at risk of ASD. In INMA, autistic traits were assessed with the Childhood Autism Spectrum Test by a psychologist at a median age of 4.6 years, with a cutoff of $15 points to define autistic traits within the clinical range (33) . In Generation R, autistic traits were assessed using the Pervasive Developmental Problems subscale of the Child Behavior Checklist for Toddlers (CBCL 1½-5) by the parents at a median age of 5.9 years, with a cutoff of $98th percentile to define autistic traits within the clinical range (34) . In ALSPAC, autistic traits were assessed with the Social Communication Disorder Checklist by the parents at a median age of 7.6 years of age, with a cutoff of nine or more points to define autistic traits within the clinical range (35) .
Potential confounding variables
A direct acyclic graph (36) facilitated decision making regarding which covariates should be adjusted for in the analysis. Information on maternal variables [age, educational level (low, medium, high), ethnicity (cohort-specific categories), parity (zero, one, two or more), prepregnancy body mass index, and smoking during pregnancy (never smoked, smoked in the beginning or until pregnancy confirmed, continued smoking)] was collected during pregnancy using questionnaires. Gestational age at blood sampling was defined using ultrasonography or the last menstrual period. Child sex and age at IQ or autistic trait ascertainment were obtained during the study visits.
Statistical analyses
We used linear regression models to study the association of maternal FT4, TSH, and thyroid disease entities with child nonverbal or verbal IQ. We used logistic regression models to study the association of maternal FT4, TSH, and thyroid disease entities with child autistic traits within the clinical range.
We studied these associations using a one-step and a twostep approach. In the one-step approach, we assessed nonlinearity between FT4 and TSH and each outcome using restricted cubic splines with three to five knots. An ANOVA test was used to report an overall P value for the null hypothesis that the mean IQ or probability of autistic traits within the clinical range was similar across the whole distribution of TSH or FT4. In the two-step approach, we combined cohort-specific effect estimates of the association between FT4, TSH, and thyroid https://academic.oup.com/jcemdisease entities and each outcome using random effects metaanalyses. For this analysis, FT4 and TSH concentrations were categorized as ,2.5th, ,5th, .95th, or .97.5th percentiles using women with values within the interquartile range (within the 25th and 75th percentile range) as the reference group. Compared with the one-step approach, the two-step approach allows for differences in participant characteristics between cohorts, and heterogeneity between cohorts can be calculated (37) . Heterogeneity was assessed using the Cochrane Q test and the I 2 statistic (38) . All models were adjusted for maternal age, educational level, ethnicity, parity, prepregnancy BMI, smoking, gestational age at blood sampling, and child sex. Because one-step approach models could not be adjusted for age at IQ or autistic trait ascertainment, cohort, and ethnicity at the same time owing to collinearity, we adjusted them only for ethnicity. The two-step approach models could be adjusted for these variables because the effect estimates were calculated separately by cohort.
As a sensitivity analysis, we adjusted the analyses of autistic traits for nonverbal IQ, a language-and culture-free measure of cognitive ability. Additionally, when we observed associations between maternal TSH and child IQ or autistic traits, we repeated the analysis stratifying by low-, mid-, and high-normal FT4. Finally, all analyses were repeated in the TPOAb-negative women only.
We applied inverse probability weighting to correct for potential differential loss to follow-up (39) . We performed multiple imputation using chained equations to account for missing values for the potential confounding variables (40) . A total of 25 data sets were generated and analyzed using standard procedures for multiple imputation. Statistical analyses were performed in STATA, version 14.0 (StataCorp, College 
Results
After exclusions, the final study population included 9036 mother-child pairs (Fig. 1) , the characteristics of which are shown in Table 1 . The mean maternal age varied across the cohorts: 31.5 years in INMA, 30.3 years in Generation R, and 28.0 years in ALSPAC. The percentage of mothers who continued smoking during pregnancy was similar among the cohorts (~16% to 17%). Autistic traits within the clinical range occurred in 1.4% of the children in INMA, 3.1% in Generation R, and 7.5% in ALSPAC. The two most prevalent thyroid disease entities were hypothyroxinemia (2.0% to 2.5% across the cohorts) and subclinical hypothyroidism (2.4% to 3.6% across the cohorts). Compared with the final study population, the women not included in the analysis had a lower level of education, were less often native or white, and were younger in all three cohorts (Supplemental Table 2 ).
Nonverbal IQ
We observed a statistically significant nonlinear association between maternal FT4 and mean nonverbal IQ (Fig. 2) . FT4 #2.5th percentile was associated with a 3.9-point (95% CI, 25.7 to 22.3; P , 0.001) lower nonverbal IQ. Similar results were observed when using the fifth percentile cutoff. A high FT4 was not associated with the nonverbal IQ. TSH $97.5th and $95th percentile was associated with a statistically nonsignificant slightly greater nonverbal IQ (1.5 points; 95% CI, 20.3 to 3.3; P = 0.100; and 1.2 points, 95% CI, 20.1 to 2.5; P = 0.063, respectively; Supplemental Fig. 1) . However, the sensitivity analysis showed that this association was driven by women with a FT4 concentration in the mid-or high-normal range (Supplemental Table 3 ). No heterogeneity was observed among the cohorts. The results remained similar after excluding TPOAb-positive women.
Verbal IQ
A statistically nonsignificant linear association was found between maternal FT4 and mean verbal IQ (Fig. 3) . FT4 #2.5th percentile was associated with a 2.1-point (95% CI, 24.0 to 20.1; P = 0.039) lower verbal IQ. In contrast, the association of FT4 at the fifth percentile or less was associated with a statistically nonsignificant slightly lower verbal IQ (21.4 points; 95% CI, 22.9 to 0.2; P = 0.078). A high FT4 was not associated with verbal IQ. A low TSH was also not associated with verbal IQ (Supplemental Fig. 2) . TSH $97.5th percentile was associated with a greater verbal IQ (1.9 points; 95% CI, 0.1 to 3.7; P = 0.039). However, no association was found for TSH $95th percentile. The sensitivity analysis showed that the positive association of a high TSH $97.5th percentile with verbal IQ was driven by women with a FT4 concentration in the mid-or high-normal range (Supplemental Table 4 ). No heterogeneity was observed among the cohorts. The results remained similar after excluding TPOAb-positive women.
Autistic traits
No continuous association was found for maternal FT4 with child autistic traits (Fig. 4) . FT4 #2.5th percentile was not associated with autistic traits, but FT4 #5th percentile was associated with a statistically nonsignificant slightly greater risk of autistic traits [odds ratio (OR), 1.5; 95% CI, 1.0 to 2.3; P = 0.080). FT4 $97.5th percentile was associated with a 1.9-fold (95% CI, 1.0 to 3.4; P = 0.043) greater risk of autistic traits. A similar association was found after adjusting for nonverbal IQ (data not shown). FT4 $95th percentile was not associated with autistic traits. TSH was not associated with autistic traits (Supplemental Fig. 3 ). No heterogeneity was observed among the cohorts. The results remained similar after excluding TPOAb-positive women.
Clinical disease entities
Highly similar results were obtained when FT4 and TSH were combined into clinical disease entities. Hypothyroxinemia, based on the 2.5th and 97.5th populationbased percentiles, was associated with a 3.8-point (95% CI, 25.7 to 22.0; P , 0.001) lower nonverbal IQ and a 2.8-point (95% CI, 24.8 to 20.7; P = 0.007) lower verbal IQ (Supplemental Fig. 4 ) but was not associated with autistic traits. For hypothyroxinemia, based on the 5th and 95th population-based percentiles, similar results were found with nonverbal and verbal IQ, with a 1.8-fold (95% CI, 1.1 to 2.8; P = 0.011) greater risk was found with autistic traits (Supplemental Fig. 4 ), which remained after adjusting for nonverbal IQ (data not shown).
Subclinical hypothyroidism, based on the 2.5th and 97.5th population-based percentiles, was associated with a 1.9-point (95% CI, 0.1 to 3.6; P = 0.037) greater nonverbal IQ but not with verbal IQ or autistic traits (Supplemental Fig. 5 ). When defining subclinical hypothyroidism using the 5th and 95th population-based percentiles, the association with nonverbal IQ became statistically non-significant (1.3 points; 95% CI, 20.2 to 2.9; P = 0.096). Subclinical hyperthyroidism was not associated with nonverbal IQ, verbal IQ, or autistic traits (Supplemental Fig. 6 ).
Discussion
To the best of our knowledge, the present study is the first individual participant data meta-analysis. We have demonstrated that low maternal FT4 in early pregnancy is associated with lower nonverbal and verbal child IQs. We also found a suggestive association between maternal Figure 2 . Association of maternal FT4 during early pregnancy with child nonverbal IQ. Association shown as (a) a continuous association depicted as the mean child nonverbal IQ (black line) with 95% CI (gray area) and by cohort-specific maternal FT4 concentrations in the (b) ,2.5th percentile, (c) .97.5th percentile, (d) ,5th percentile, and (e) .95th percentile compared with interquartile range (between 25th and 75th percentiles), depicted as effect estimate (dot) with the 95% CI per cohort and overall as estimated by random effects meta-analysis (diamond). The I 2 for each model was as follows: for FT4 ,2.5th percentile, I 2 = 0.0%; for FT4 .97.5th percentile, I 2 = 48.5%; for FT4 ,5th percentile, I 2 = 0.0%: for FT4 .95th percentile, I 2 = 37.8%. percentile compared with interquartile range (between 25th and 75th percentiles) depicted as effect estimate (dot) with 95% CI per cohort and overall as estimated by random effects meta-analysis (diamond). The I 2 for each model was as follows: for FT4 ,2.5th percentile, I 2 = 7.4%; for FT4 .97.5th percentile, I 2 = 0.0%; for FT4 ,5th percentile, I 2 = 0.0%; for FT4 .95th percentile, I 2 = 0.0%.
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hypothyroxinemia and high FT4 with a greater risk of autistic traits within the clinical range. In contrast to FT4, maternal TSH was not independently associated with nonverbal IQ, verbal IQ, or autistic traits within the clinical range. The association between low maternal FT4 and child IQ, specifically nonverbal IQ, was highly similar among the three cohorts, convincingly replicating the results of previous observational studies (4) (5) (6) (7) (8) (9) . A recent randomized controlled trial studied the effects of levothyroxine treatment for women with subclinical hypothyroidism or hypothyroxinemia on child full IQ (21) . Although levothyroxine treatment of hypothyroxinemia or subclinical hypothyroidism started in mid-pregnancy (weeks 16 to 18), a statistically nonsignificant 1.3 points greater median child IQ was found after levothyroxine treatment compared with placebo. The associations of hypothyroxinemia with a 3.8-and 2.8-point lower nonverbal and verbal IQ, respectively, found in our study compared with euthyroid women might seem small on an individual level. However, on a population level, this might have effects on educational achievements and capita per income, among others (41) .
The consistent association of low maternal FT4 with adverse child neurocognitive outcomes, specifically lower nonverbal IQ in three independent cohorts, is particularly relevant given that all three cohorts used a different immunoassay to measure FT4. The value of an FT4 measurement during pregnancy has been under debate, because the absolute values of FT4 might have been under-or overestimated when measured using immunoassays in pregnancy, especially in the third trimester (42) (43) (44) . However, these results suggest that FT4 is a reliable clinical marker of the fetal thyroid state in early pregnancy, a period when maternal FT4 is the sole source of thyroid hormones for the fetus and influences the developmental processes, including proliferation, migration, and differentiation of neuronal cells in various parts of the brain (45) . No conclusions about the use of FT4 assays during the later stages of pregnancy, when the fetal thyroid is fully functional, should be drawn from these data.
In our study, the effect estimates for nonverbal IQ were larger than for those for verbal IQ. Nonverbal IQ is a language-and culture-free measure of cognitive ability that is less dependent on the learning stimulus received by the child during the first years of life. Therefore, it might be a better neurodevelopmental outcome for detecting the effects of maternal exposures in early pregnancy, such as thyroid hormone levels.
Our results did not show an association between high maternal FT4 and nonverbal or verbal IQ across the three cohorts, although we confirmed the previously reported association with the Generation R data (4) . The discrepancies in the association of high FT4 and nonverbal IQ among the cohorts might have resulted from population differences such as maternal iodine status, which differed considerably among the cohorts. Pregnant women in Generation R had an adequate iodine status according to the World Health Organization [median urinary iodine concentration, 229.6 mg/L (19)]. In contrast, mild to moderate iodine insufficiency was present in the INMA and ALSPAC cohorts [median, 94 to 168 mg/L depending on the region and 91.1 mg/L, respectively (46, 47) ]. Although mild-tomoderate iodine deficiency has been associated with adverse neurodevelopmental outcomes, such as lower verbal IQ, worse language skills, reduced educational outcomes, impaired executive function, more behavior problems, and worse fine motor skills, this was not found in iodine-deficient women in an iodine sufficient population (19, (48) (49) (50) . It is unclear how much of the association of iodine deficiency with child neurocognitive outcomes can be attributed to impaired thyroid function in the mother or to impaired thyroid function in the fetus. Further studies should elucidate the mediating role of maternal and fetal thyroid function in the association between maternal iodine and child neurodevelopment.
To date, only two studies have explored the association between maternal thyroid function and ASD diagnosis or autistic traits. The Danish study was based on registry linkage information and showed that maternal diagnosed or treated hypothyroidism was associated with a greater risk of diagnosed ASD (hazard ratio, 1.30; 95% CI, 1.11 to 1.53) (51). The Dutch study from the Generation R cohort found that severe hypothyroxinemia, defined as maternal FT4 fifth percentile or less with normal TSH, was associated with a greater risk of autistic traits (9) . In the present metaanalysis of data from Generation R, we also found an association between hypothyroxinemia using the FT4 fifth percentile or less cutoff and a greater risk of autistic traits. However, when using the FT4 #2.5th percentile cutoff, no greater risk of autistic traits was found, suggesting the possibility of a chance finding. Likewise, high FT4 was associated with a greater risk of autistic traits, although only when the more stringent cutoff was used (i.e., FT4 $97.5th percentile). Considering the crucial role of thyroid hormones in key processes in the pathophysiology of ASD, including neuronal cell migration, synaptogenesis, synapse maintenance, neuronal activity, and fetal growth (52, 53) , it is biologically plausible that nonoptimal levels of maternal FT4 during early pregnancy are related to a greater risk of ASD. However, the inconsistent results across cohorts or cutoffs limited us from drawing firm conclusions regarding this potential association. Further studies focusing on autistic traits or ASD diagnosis are therefore needed to replicate and better understand the full extent of these results.
TSH is frequently used as a marker of thyroid status during pregnancy. Subclinical hypothyroidism has been associated with a greater risk of miscarriage and preterm delivery, and the beneficial effects of levothyroxine treatment for hypothyroid women have been shown in some trials, especially in TPOAb-positive women (54) (55) (56) (57) . Therefore, the current international guidelines recommend screening for TSH first, either directly in combination with determining TPOAb status (27) or determining TPOAb status and FT4 only when TSH is elevated (58) . The results from the present study call into question the use of TSH as the only firstline parameter to screen maternal thyroid status in early pregnancy. First, elevated human chorionic gonadotropin concentrations stimulate the thyroid directly to produce thyroid hormone, which induces a decrease in TSH in early pregnancy (59) . Therefore, TSH might not be the best marker for maternal thyroid status in this period. Second, in our study, maternal TSH was not independently associated with nonverbal IQ, verbal IQ, or autistic traits, in contrast to FT4. However, owing to the absence of available randomized trials demonstrating the benefit of levothyroxine treatment for maternal hypothyroxinemia, screening for FT4 cannot be advocated.
One strength of the present study was that we investigated the association of maternal thyroid function with child neurodevelopmental outcomes in a prospective manner using a large data set with detailed data on nonverbal IQ, verbal IQ, and autistic traits, assessed using validated tools. Furthermore, by combining data from three different countries, we were able to perform an external replication of previous studies and assess potential differences related to iodine status, after adjusting for many potential confounding variables. We also used advanced statistical methods, including multiple imputation combined with inverse probability weighting, to reduce possible selection bias.
One limitation of the present study was that the child neurodevelopmental outcomes were assessed with different tools at different ages. This might be, for example, reflected in the different prevalence of children with autistic traits within the clinical range across cohorts. The varying occurrence might have resulted from the different ages at the assessment and/or the different types of evaluator but most likely resulted from the different set of questions for assessing autistic traits. For instance, the Childhood Asperger Syndrome Test (CAST) (33) contains 31 items and is therefore a more extensive questionnaire compared with the CBCL 1½-5, with 13 items (34) , and the Social and Communication Disorders Checklist (SCDC), with 12 items (35) . The CAST and CBCL 1½-5 cover questions on all three domains of ASD. In contract to the CAST and CBCL 1½-5, the SCDC was designed to assess deficits in social and communications skills but does not assess the ASD domain of restricted and repetitive behaviors and interests. To account for the differences as best as possible, we standardized all outcome scores and adjusted all analyses for child age at the IQ or autistic traits ascertainment. We observed little heterogeneity among the cohorts. Another limitation was the low prevalence children with autistic traits within the clinical range, which caused, especially in INMA, issues with statistical power. Furthermore, we only had a single thyroid function measurement available from early pregnancy. Hence, the results should not be generalized to thyroid function in late pregnancy, and the potential effects of individual variations in maternal thyroid hormone availability could not be studied.
In conclusion, the results from the present study have confirmed that a low FT4 is consistently associated with a lower child IQ. We also found a suggestive association of maternal hypothyroxinemia and high FT4 with a greater risk of autistic traits within the clinical range. FT4 seemed a reliably marker of the fetal thyroid state in early pregnancy, regardless of the type of immunoassay used. Further studies should replicate the findings of autistic traits and investigate the potential modifying role of maternal iodine status.
